FDA reviewers raised no serious efficacy or safety concerns about Moderna's mRNA flu vaccine candidate for adults 50 and older, which has the potential to become the first such product approved by the agency.
Read more at: https://www.medpagetoday.com/infectiousdisease/uritheflu/121795
Moderna's novel vaccine was at the center of dustup with agency earlier this year
